- •Mistral Large 2512 argues HOLD because LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technically, the stock is trading above key support levels ($1161.39 and $1165.80) and within the value area, with RSI and MACD confirming trend participation. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
- •DeepSeek V4 Flash argues EXIT because The breakout above $1186 resistance has failed — price rejected and fell back below it with deteriorating momentum (RSI and MACD both falling) on depressed volume. LLY is underperforming its own sector (XLV +0.21% vs LLY -0.25%), signaling idiosyncratic weakness. The regime has shifted from calm/bullish to No Edge/neutral with medium risk, removing the supportive macro backdrop. The original premortem rejection scenario is activating, and with only 14.6% progress toward target, the risk/reward has shifted against holding.
- •What changed: Price rejected from the $1185.85-$1188.44 resistance zone and fell back to $1178.94, confirming a failed breakout. 4h RSI and MACD histogram both reversed from rising to falling. LLY began underperforming XLV. Regime shifted from calm/bullish to No Edge/neutral.
LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technically, the stock is trading above key support levels ($1161.39 and $1165.80) and within the value area, with RSI and MACD confirming trend participation. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
LLY holds above the $1161-$1166 support shelf and its SMA20/SMA50 with 1day RSI rising and MACD histogram expanding, exactly the constructive structure the entry anticipated, and a fresh Sep 24 Onswik FDA approval stacks on the Inluriyo/Verzenio and Mounjaro catalysts that drive the fundamental story. The stop at $1140 is untouched, price is +0.9% from entry, and the $1240 target remains feasible with only the $1186 barrier left to reclaim. Strong fundamentals (33.5% margins, +27% EPS surprise, dominant GLP-1 share) keep the multi-week swing thesis intact.
The breakout above $1186 resistance has failed — price rejected and fell back below it with deteriorating momentum (RSI and MACD both falling) on depressed volume. LLY is underperforming its own sector (XLV +0.21% vs LLY -0.25%), signaling idiosyncratic weakness. The regime has shifted from calm/bullish to No Edge/neutral with medium risk, removing the supportive macro backdrop. The original premortem rejection scenario is activating, and with only 14.6% progress toward target, the risk/reward has shifted against holding.
- →The single most likely reason the HOLD verdict is wrong is if price fails to reclaim the $1186.80 resistance level and instead breaks below the $1161.39 support, invalidating the original thesis and closing the path to the $1240 target.
- →Failed breakout at $1186 resistance with deteriorating momentum, sector underperformance, and regime deterioration — the original premortem rejection scenario is activating.
Individual Model Review
LLY holds above the $1161-$1166 support shelf and its SMA20/SMA50 with 1day RSI rising and MACD histogram expanding, exactly the constructive structure the entry anticipated, and a fresh Sep 24 Onswik FDA approval stacks on the Inluriyo/Verzenio and Mounjaro catalysts that drive the fundamental story. The stop at $1140 is untouched, price is +0.9% from entry, and the $1240 target remains feasible with only the $1186 barrier left to reclaim. Strong fundamentals (33.5% margins, +27% EPS surprise, dominant GLP-1 share) keep the multi-week swing thesis intact.
LLY holds above the $1161-$1166 support shelf and its SMA20/SMA50 with 1day RSI rising and MACD histogram expanding, exactly the constructive structure the entry anticipated, and a fresh Sep 24 Onswik FDA approval stacks on the Inluriyo/Verzenio and Mounjaro catalysts that drive the fundamental story. The stop at $1140 is untouched, price is +0.9% from entry, and the $1240 target remains feasible with only the $1186 barrier left to reclaim. Strong fundamentals (33.5% margins, +27% EPS surprise, dominant GLP-1 share) keep the multi-week swing thesis intact.
▼ Click to expandThe regime has flipped from calm/bullish to No Edge/neutral with medium risk, and price has slipped back below the $1186 resistance it briefly cleared at the prior review while 4h momentum cools (RSI and MACD histogram falling) on depressed volume at the 8th percentile. A HIGH-impact macro cluster on Sep 30-Oct 2 raises the odds of a risk-off pullback that breaks the $1161 support shelf before the $1240 target is reached, which would invalidate the breakout path and justify closing the position.
▼ Click to expandThe breakout above $1186 resistance has failed — price rejected and fell back below it with deteriorating momentum (RSI and MACD both falling) on depressed volume. LLY is underperforming its own sector (XLV +0.21% vs LLY -0.25%), signaling idiosyncratic weakness. The regime has shifted from calm/bullish to No Edge/neutral with medium risk, removing the supportive macro backdrop. The original premortem rejection scenario is activating, and with only 14.6% progress toward target, the risk/reward has shifted against holding.
Failed breakout at $1186 resistance with deteriorating momentum, sector underperformance, and regime deterioration — the original premortem rejection scenario is activating.
The breakout above $1186 resistance has failed — price rejected and fell back below it with deteriorating momentum (RSI and MACD both falling) on depressed volume. LLY is underperforming its own sector (XLV +0.21% vs LLY -0.25%), signaling idiosyncratic weakness. The regime has shifted from calm/bullish to No Edge/neutral with medium risk, removing the supportive macro backdrop. The original premortem rejection scenario is activating, and with only 14.6% progress toward target, the risk/reward has shifted against holding.
▼ Click to expandThe original catalyst thesis of FDA approvals (Onswik, Inluriyo, Mounjaro) and strong Foundayo adoption remains fundamentally intact. Price is still above the $1161.39 support shelf and the $1140 stop provides a well-defined risk boundary. The pullback from $1188.33 could be a healthy retest before the next leg higher toward $1240 within the remaining 11 days.
▼ Click to expandLLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technically, the stock is trading above key support levels ($1161.39 and $1165.80) and within the value area, with RSI and MACD confirming trend participation. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
LLY's original thesis remains intact, supported by fresh FDA approvals for Onswik and prior catalysts (Inluriyo+Verzenio and Mounjaro label expansion), which expand the company's addressable markets and reinforce fundamental growth. Technically, the stock is trading above key support levels ($1161.39 and $1165.80) and within the value area, with RSI and MACD confirming trend participation. The path to the $1240 target is still feasible, and the stop at $1140 has not been compromised.
▼ Click to expandThe exit case would strengthen if LLY fails to reclaim the $1186.80 resistance level and breaks below the $1161.39 support, signaling a failed breakout and invalidating the original thesis. Additionally, if the Healthcare sector (XLV) weakens further or macro regime shifts materially disrupt risk appetite, the risk/reward for the position would deteriorate.
▼ Click to expandRun Summary
Intraday discovery triggered reanalysis on LLY. Verdict: HOLD (1/3 EXIT; requires 2). Conviction: 66.